首页|'Auto High Content Screening Using Artificial Intelligence For Drug Compound Development' in Patent Application Approval Process (USPTO 20240029403)
'Auto High Content Screening Using Artificial Intelligence For Drug Compound Development' in Patent Application Approval Process (USPTO 20240029403)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
A patent application by the inventors Dodkins, Henry Rupert (Santa Barbara, CA, US); Fedorov, Dmitry (Santa Barbara, CA, US); Findley, Teresa (Santa Barbara, CA, US); Goldberg, Ilya (Santa Barbara, CA, US); Kvilekval, Kristian (Santa Barbara, CA, US); Lang, Christian A. (Santa Barbara, CA, US); Yeung, Katherine (Santa Barbara, CA, US), filed on June 27, 2023, was made available online on January 25, 2024, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institution. The following quote was obtained by the news editors from the background information supplied by the inventors: “Various chemicals combined in compounds are often screened by drug or pharmaceutical companies to develop new drugs to treat various issues of biological cells found in various lifeforms, such as plants, animals, and human beings. The drug development process is a lengthy process with multiple steps or phases.
Artificial IntelligenceEmerging TechnologiesGeneticsGovernment Agencies Offices and EntitiesMachine LearningPatent Application
NETL
NSTL
